Acurx Pharmaceuticals, Inc., incorporated in Delaware in July 2017, began operations in February 2018. The Company is a late-stage biopharmaceutical company focused on the development of novel small molecule antibiotics for refractory bacterial infections for the treatment of infections caused by bacteria classified as priority pathogens by the World Health Organization (" WHO "), the U.S. Centers for Disease Control and Prevention (" CDC ") and the U.S. Food and Drug Administration (" FDA "). Priority pathogens are those that require new antibiotics to address the global antimicrobial resistance (" AMR ") crisis identified by the WHO, CDC and FDA. 

ACXP

ACXP Profile